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Background: Single nucleotide polymorphisms (SNPs) within the LOXL1 gene are associated with pseudoesfoliation
syndrome and pseudoesfoliation glaucoma. The aim of our study is to investigate a potential involvement of LOXL1
gene in the pathogenesis of pigment dispersion syndrome (PDS) and pigmentary glaucoma (PG).
Methods: A cohort of Caucasian origin of 84 unrelated and clinically well-characterised patients with PDS/PG and
200 control subjects were included in the study. Genomic DNA from whole blood was extracted and the coding
and regulatory regions of LOXL1 gene were risequenced in both patients and controls to identify unknown sequence
variations. Genotype and haplotype analysis were performed with UNPHASED software. The expression levels of LOXL1
were determined on c-DNA from peripheral blood lymphocytes by quantitative real-time RT-PCR.
Results: A significant allele association was detected for SNP rs2304722 within the fifth intron of LOXL1 (Odds ratio (OR
= 2.43, p-value = 3,05e-2). Haplotype analysis revealed the existence of risk and protective haplotypes associated with
PG-PDS (OR = 3.35; p-value = 1.00e-5 and OR = 3.35; p-value = 1.00e-4, respectively). Expression analysis suggests that as-
sociated haplotypes can regulate the expression level LOXL1.
Conclusions: Haplotypes of LOXL1 are associated with PG-PDS independently from rs1048661, leading to a differential
expression of the transcript.
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Glaucoma, the leading global cause of irreversible visual
impairment and blindness, is a group of chronic, pro-
gressive optic neuropathies that have in common char-
acteristic morphological changes at the optic nerve head
and retinal nerve fibre layer [1]. The cause of glaucomat-
ous neuropathy is unknown; previous studies have sug-
gested that multiple factors, including multiple genetic
factors, might be responsible for this condition. Pigment
dispersion syndrome (PDS) and pigmentary glaucoma (PG)
are the most common non-traumatic causes of glau-
coma in young adults and are characterised by disruption
of the iris pigment epithelium and deposition of abnormal* Correspondence: lucia.tanga@gmail.com
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reproduction in any medium, provided the orpigment granules throughout the anterior segment, which
results in aqueous outflow obstruction [2].
Like the majority of human diseases PG and PDS show a
familial aggregation that does not usually follow Mendelian
family patterns but is caused by an unknown number
of multiple genes, usually interacting with various envir-
onmental factors. A single susceptibility locus to PDS has
been mapped on chromosome 7q35-q36 but the candidate
gene is yet to be identified [3].
Pseudoexfoliation syndrome (PEXS) is the most common
identifiable cause of open-angle glaucoma, accounting for
approximately 25% of all open-angle glaucoma worldwide
[4]. It is an age-related systemic disease of the extracellular
matrix characterized by the multifocal production and pro-
gressive accumulation of a fibrillar extracellular material in
intra and extra-ocular tissues that is either the result of an
excessive production or insufficient breakdown or both [5].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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mon identifiable cause of openangle glaucoma, accounting
for approximately 25% of all open-angle glaucoma world-
wide [4]. It is an age-related systemic disease of the extra-
cellular matrix characterised by the multifocal production
and progressive accumulation of a fibrillar extracellular
material in intra- and extraocular tissues, which is either
the result of excessive production, insufficient breakdown
or both [5]. PEXS and PDS are two disorders that can
produce secondary glaucoma through trabecular blockage
[2,6] Secondary open-angle glaucoma because of PEXS
(PEXG) develops from the deposition of exfoliation ma-
terial in the trabecular meshwork, leading to elevated
intraocular pressure (IOP) and consequently glaucomat-
ous optic neuropathy [7].
Recently, a genome-wide association study demon-
strated that one intronic single nucleotide polymorphism
(SNP) (rs2165241) and two non-synonymous coding
SNPs (rs1048661 (R141L) and rs3825942 (G153D)), lo-
cated in the first exon of the LOXL1 gene (15q24-q25),
confer risk to PEXG through PEXS in the Icelandic and
Swedish populations [8]. Several following studies rep-
licated the association of these two nonsynonymous
SNPs with exfoliation syndrome (XFS) in different popu-
lations [7,9-14].
The aim of our study was the mutational analysis of
the coding and regulatory regions of LOXL1 to disclose
unknown variants and/or haplotypes associated with the
development of pigment PDS and PG.
Methods
Study subjects
Unrelated Italian patients with clinically well-characterised
PDS/PG and healthy control subjects were recruited at the
moment of referral at the glaucoma unit of the Bietti Eye
Foundation IRCCS, Rome, Italy and the ophthalmology
clinic of the University of Tor Vergata, Rome, Italy. The
study was approved by the local ethics committee (Ethics
Committee of the University of Tor Vergata, R. S. 91.10,
24/09/2010) and adhered to the tenets of the Declaration
of Helsinki and local law.
Written informed consent was obtained before enrol-
ment from all subjects. After the collection of demographic
and historical data, all enrolled subjects underwent a
complete detailed ophthalmological examination including
(i) corrected visual acuity (ETDRS), (ii) slit lamp biomicro-
scopy examination of the anterior segment, (iii) gonioscopic
evaluation of the anterior chamber angle using a one mirror
high magnification gonio lens (MagnaView Gonio laser
lens), (iv) measurement of IOP using Goldmann applana-
tion tonometry and (v) indirect ophthalmoscopy using a
90D Volk’s lens. Moreover, the visual field (VF) was tested
in all subjects using the Humphrey Field Analyzer 24-2
test pattern and SITA standard threshold strategy.Subjects with PDS were defined as those with an open
angle at gonioscopy, trabecular meshwork pigmentation,
the presence of a Krukenberg spindle and midperipheral
iris transillumination. Subjects with PG were defined as
those with a documented history of IOP > 24 mmHg,
optic disc and confirmed VF damage (defined as a glau-
coma hemifield test result outside normal limits, MD
and PSD outside 95% confidence limits and a cluster of
at least three points with P < 0.05 in the pattern devi-
ation plot, with one of each with P < 0.01 affecting the
same hemifield).
Common exclusion criteria for PDS/PG were a history
of ocular surgery or traumas, any active ocular pathology
different from glaucoma, PEXS or PEXG, other causes
of secondary glaucoma or a history of long-term use of
topical or systemic steroids.
Healthy subjects with no history of IOP > 22 mmHg in
both eyes, open angle at gonioscopy, normal anterior seg-
ment, normal appearance of optic disc and normal VF
were recruited as controls.
Genotyping
Genomic DNA was extracted from peripheral white blood
cells of all subjects using the QIAamp DNA blood
mini kit (Qiagen Ltd, Valencia, CA, USA). The coding
and regulatory regions of LOXL1 were resequenced in
both patients (n = 84) and healthy controls (n = 100) using
sequence specific primers (Table 1). PCR products were
purified using an ultraclean PCR purification kit (DyeEx
Kits, Qiagen, Hilden, Germany) and sequenced in an ABI
3130 × l sequencer using a Big Dye 3.1 terminator ready
reaction kit (Applied Biosystems, California, USA). DNA
sequences were analysed using the sequencing analysis 3.0
software package (Applied Biosystems, California, USA).
The genotyping of rs1048661, rs3825942 and rs2304722
was performed in an extended control cohort (n = 100)
by TaqMan assays. Reactions were run in an AB7500
(Applied Biosystems, California, USA) and interpreted
using Sequence Detection System (SDS) 2.1 software.
Real-time PCR
The generation of first-strand cDNA was performed using
a high capacity DNA reverse transcription kit (Applied
Biosystems) according to the manufacturer’s instructions,
and the reverse transcriptase reaction products were
used for quantitative real-time PCR, which was run in
an AB7500 (Applied Biosystems) using TaqMan pre-
designed probes (Hs00935937_m1).
The amount of mRNA for LOXL1 in each sample was
normalised to the amount of mRNA of the beta 2-tubulin
reference gene in the same sample. Relative mRNA ex-
pression levels of all examined genes were measured using
the comparative 2 ΔΔCT Ct method. Each plate contained
three positive controls (samples previously confirmed by
Table 1 Self-designed primers used for LOXL1 resequencing
Forward 5′-3′ Reverse 5′-3′ Amplicons size (bp)
Exon 1 GCAGGTGTACAGCTTGCTCA ACACGAAACCCTGGTCGTG 420
Intron 1 GCAGAAGGGCGATTATAGC CATGTGAGTACACAGCTTG 392
Exon 2 CTGATGCTCTCAATGCATGC CTTGCAGACAGCCTAGCTG 228
Exon 3 CATGCTGGGTTCTGGTGTCA CTAATCCAGTATCTGTCTC 258
Exon 4 GACTAGGCCCTCTTCTTTCTC CGCTCTTTGCCTCCCCAAC 224
Exon 5 CAGAAACTCCTGAAGGTGGG GCTGAAGCTTCTTTCAGGAAC 240
Exon 6 CTCTCTGTCTGTCTGTCTGC CTGCGTTCGGCCATCAAGG 304
Exon 7 GAAATGTAGGCCCATGCTG GAAGGATGATGCCTAAGGAC 486
Table 2 Location and allele frequencies of sequence
variation identified in PDS/PG cases and controls
Position SNP Variation PDS*/PG† Controls P
Exon 1 rs1048661 G/T G = 0.66 G = 0.71 NS‡
T = 0.34 T = 0.29
Exon 1 rs3825942 G/A G = 0.84 G = 0.8 NS
A = 0.16 A = 0.2
Exon 1 rs2165241 C/T C = 0.51 C = 0.50 NS
T = 0.49 T = 0.50
Intron 5 rs2304722 C/T C = 0.09 C = 0.21 1.62e-4
T = 0.91 T = 0.79
Exon 7 rs8818 G/C G = 0.69 G = 0.68 NS
C = 0.31 C = 0.32
Exon 7 rs3522 C/T T = 0.44 T = 0.45 NS
C = 0.56 C = 0.55
*Pigmentary Dispersion Syndrome; †Pigmentary Glaucoma; ‡Not significant.
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and two negative controls.
Statistical analysis
Statistical analyses were performed using a standard 2× 2
table and Fisher’s exact tests. Allele and genotype frequencies
of each sequence variant were compared between patients
and healthy controls. Haplotype analysis in unrelated samples
was performed using the software UNPHASED, available at
https://sites.google.com/site/fdudbridge/software/unphased-3-
1. Odds ratios (ORs) were calculated using the online
software “calculator for confidence intervals of OR in an
unmatched case control study” available at http://www.
hutchon.net/ConfidOR.htm. Linkage disequilibrium (LD) was
evaluated by LD plotter available at http://www.pharmgat.org.
RNA preparation
Total RNA was extracted from lymphocyte cells with an
RNAeasy mini kit (Qiagen, Hilden, Germany) as per the
manufacturer’s instructions. RNA was then eluted in
30 μl of RNase-free water and stored at –80°C.
Results
Altogether, 84 PDS/PG patients (mean age 48.0 ± 4.9 years,
40 females and 44 males), and 200 healthy control subjects
(mean age 46.7 ± 5.2 years, 97 males and103 females) were
enrolled in this study.
The regulatory and coding regions of LOXL1 were rese-
quenced in all enrolled PG/PDS control subjects to iden-
tify sequence variants. Table 2 reports a list of identified
sequence variants and allele and genotype frequency in
our cohort of patients and controls. No departure from
the Hardy–Weinberg equilibrium was detected for all
SNPs identified. Allele frequencies of SNPs rs1048661 and
rs3825942, associated to pseudoexfoliation syndrome and
pseudoexfoliation glaucoma [8], showed weak differences
between cases and controls, although they didnot reach
significance (Table 2). We failed to reveal differences in al-
lele and genotype frequency for rs2165241. Notably, a sig-
nificant association for rs2304722 (intron 5) was detected
in PG/PDS patients (Table 2) with the T allele showing afrequency of 0.90 in PG/PDS patients and 0.80 in control
subjects (OR = 2.43, pvalue = 3.05e-2).
Pairwise LD analysis for all identified SNPs revealed
differences in LD patterns between cases and controls
(Figure 1). LD patterns suggested the existence of a con-
served block between markers rs1048661 and rs2165241
associated with the disease. The extent of LD was differ-
ent between the case and control groups, confirming the
region between rs1048661 and rs2304722 as a locus of
putative association.
Afterwards, a fine mapping of specific haplotype sub-
sets within the block was performed to narrow the minimal
associated chromosomal region. As expected, haplotype
analysis confirmed the LD findings revealing a highly
associated haplotype for markers rs1048661, rs3825942
and rs2304722. Haplotype harbouring of the T allele of
rs1048661, G allele of rs3825942 and T allele of rs2304722
was significantly over-represented only in PG/PDS cases
(OR = 3.35; p-value = 1.0e-5) (Table 3). Conversely, haplo-
type harbouring of the T allele of rs1048661, G allele of
rs3825942 and C allele of rs2304722 was significantly
under-represented in PG/PDS chromosomes (OR = 3.35;
Figure 1 Linkage Disequilibrium patterns in both cases (left) and controls (right). The extent of LD is higher in cases chromosomes than in
control chromosomes. Cases: rs1048661-rs3825942 D’ = 1; rs3825942- rs2304722 D’ = 1; rs1048661-rs2304722 D’ = 1. Controls: rs1048661-rs3825942
D’ = 0.73; rs3825942- rs2304722 D’ = 0.51; rs1048661-rs2304722 D’ = 0.96.
Table 3 LOXL1 Haplotypes in PDS/PG cases and controls
Haplotype* No. (%)
of PDS/PG
patients
No. (%) of
control
subjects
OR (95% CI) P
GGT 0.50 0.51 0.96 (0.66-1.40) NS
GAT 0.16 0.20 0.79 (0.48-1.31) NS
TGC 0.09 0.20 0.41 (0.23-0.76) 1e-4
TGT 0.25 0.09 3.35 (2.02-5.58) 1e-5
*Haplotypes are from rs1048661-rs3825942-rs2304722.
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distribution in case and control chromosomes revealed
that risk and protective haplotypes shared the same al-
leles at loci rs1048661 and rs3825942, suggesting a role
for rs2304722. By contrast, haplotypes GGTand GAT, har-
bouring the T allele of rs2304722, were unassociated in our
cohort, ruling out a direct functional role for this allele.
Previous data on adipose tissues have shown that the
expression of LOXL1 is decreased by 7.7% per risk allele
of SNP rs1048661 (R141L) in PEXS and pseudoexfolia-
tion glaucoma [8]. To verify if the associated haplotypes
could affect the expression levels of LOXL1, independently
from the rs1048661 genotype, we compared the lympho-
cyte expression patterns of LOXL1 between patients homo-
zygous for risk, protective and neutral haplotype. We
performed a quantitative real-time reverse transcrip-
tion PCR (qRT-PCR) assay on lymphocyte cells from
nine healthy samples. Three samples were homozygous
for the neutral haplotype, three samples were homozygous
for the protective haplotype and three samples were
homozygous for the risk haplotype.
Expression analysis revealed that samples harbouring
the risk haplotype showed a decrease of expression levels
of LOXL1 (9%) with respect to the neutral (unassociated)
haplotype. Interestingly, expression levels of LOXL1 in-
creased in the sample homozygous for the protectivehaplotype (26%) with respect to the samples harbouring
neutral haplotypes (Figure 2).
Discussion
We found that common sequence variants of LOXL1
gene are associated with an increased risk of PDS/PG.
Our results are in accord with the findings of Rao and
colleagues [15] in that there is no significant association for
the LOXL1 SNPs (rs1048661 and rs3825942) with PEXG
in PG/PDS only [8].
In our study, the full sequencing of the LOXL1 gene
allowed us to identify that a different sequence variation,
rs2304722, is strongly associated with PDS/PG.
Markers rs1048661 and rs3825942 are statistically associ-
ated with the disease only when combined with rs2304722.
0,6
0,8
1
1,2
1,4
1,6
TT/GG/CC Reference GG/GG/TT TT/GG/TT
Figure 2 LOXL1 mRNA expression in lymphocytes of samples homozygous for risk haplotype (TGC), neutral haplotype (GGT) and
protective haplotype (TGT). LOXL1 mRNA expression in “at risk individuals” and “protective individuals” was respectively lower 0.91 (95% C.I.
0,85-0,98) C.I. and higher 1,26 (95% C.I. 1,08-1,49) than that in individuals harbouring neutral (non associated) haplotype 1,00 (95% C.I. 0,94-1,05).
Beta 2-tubulin was used to normalize for any differences in mRNA.
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by expression analysis, revealing the existence of a differ-
ential regulation of LOXL1 mRNA in samples harbouring
the risk or protective haplotypes. These data suggest that
the downregulation of LOXL1 is independent from the
rs1048661 genotype and is associated with the susceptibil-
ity to PG/PDS. It should also be outlined that the associ-
ation of rs2304722 might reflect the presence of a genuine
association owing to LD with another, putatively causal
polymorphism in the adjacent LOXL1 gene region. The
genetic association of LOXL1 SNPs and the expression
analysis in PDS/PG support our hypothesis of a functional
role of the product of the LOXL1 gene in the pathogenesis
of pigmentary disorders. The expression levels of LOXL1
were determined on c-DNA from peripheral blood lym-
phocytes by quantitative real-time RT-PCR, since it is dif-
ficult to obtain tissue from eye tissues.
The LOXL1 gene, a member of the lysyl oxidase family,
consists of seven exons, five of which (exon 2–exon 6) are
of similar size and encode proteins with 76% amino acid
identity. 16 Exon 1 codes for a signal peptide, a putative
pro-enzyme region, and the beginning of a mature enzyme
[16]. Lysyl oxidases are extracellular copperrequiring en-
zymes that catalyse the cross-linking of collagen and
elastin through the oxidative deamination of a lysine
or hydrolysine side chain, with the consequential for-
mation of elastin polymer fibres [16,17]. The elastic
fibres are components of the extracellular matrix and
confer resilience [16].
Liu et al. showed that mice lacking LOXL1 do not de-
posit normal elastic fibres in the uterine tract postpartum
and develop pelvic organ prolapse, enlarged airspaces of
the lung and loose skin and vascular abnormalities with
concomitant tropoelastin accumulation [18].Conclusion
The pathogenesis of PG has not yet been characterised,
and it has been hypothesised that a major role is exerted
by the presence of iris concavity, which leads to iridozo-
nular friction and iris pigmented epithelium disruption.
The findings of our study support the hypothesis of the
presence of defects in the stromal iris elastic fibres link-
ing to the mutation of the LOXL1 gene that could justify
the presence of the increased iris concavity frequently pre-
sented in PDS/PG. The results of this work, which need to
be confirmed by independent studies, suggest new insights
on the molecular basis of iris pigment dispersion and re-
lated glaucoma, with presumed benefits for the screening
and management of diseases.
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